FTPP (Adipotide) 5 mg (1 vial)

The research utility of FTPP Adipotide Peptide lies in its ability to differentiate between the vasculature of white adipose tissue and that of other organs, a feat achieved through its precise two-domain sequence.

Key Areas of Laboratory Investigation:

• Targeted Homing (CKGGRAKDC): The amino-terminal domain is a cyclic peptide designed to bind with high affinity to Prohibitin (PHB) and Annexin A2, proteins that are selectively expressed on the endothelial cells of blood vessels feeding white adipose tissue.

   

• Mitochondrial Disruption (KLAKLAK)$_2$: Once the peptide binds and is internalized via receptor-mediated endocytosis, the carboxyl-terminal domain—consisting of D-amino acids for enhanced stability—targets the mitochondrial membrane. Research indicates it induces the release of cytochrome c, triggering the apoptotic cascade.

   

• Ischemic Adipocyte Turnover: By inducing apoptosis in the supporting vasculature, researchers observe the subsequent “starvation” and resorption of the associated adipocytes. This model is used to study the systemic endocrine consequences of rapid adipose reduction.

   

• Metabolic Sensitivity: Studies in primate and rodent models suggest that FTPP Adipotide Peptide exposure may lead to rapid improvements in insulin sensitivity and glucose handling, often occurring before significant fat mass is lost, indicating a direct effect on metabolic signaling.

Chemical & Technical Specifications